Abstract:Objective To study the impedance detected by the whole blood electrical impedance aggregometry in evaluating the effect of antiplatelet therapy.Methods The imprecision of the two different assays(the whole blood electrical impedance aggregometry and the plasma light transmission aggregometry) was compared.Thirty healthy volunteers and 60 patients with coronary artery disease under antiplatelet treatment were enrolled in the present study,whose anti-aggregated blood were collected for the measurement of electrical impedance in the presence of ADP,arachidonic acid and collagen,respectively.Finally,we analysed the agreement between the results of the two different assays which were used to measured the antiplatelet effect of aspirin and clopidgrel.Results The imprecision analysis showed the CV,(the whole blood electrical impedance aggregometry was 4.8%,superior to the plasma light transmission aggregometry (CV = 7.7%).In healthy control group,the mean impedances were(9.6±3.4)Ω、(10.4±2.8)Ω and (13.5±2.2)Ω in the presence of ADP,arachidonic acid and collagen as in the patients taking aspirin 100 mg/day,the 95% patients' results were 0 Ω.Furthermore,the mean impedance of patients taking aspirin 100 mg/day and/or clopidogrel 75 mg/day was significantly lower than that of healthy volunteers(ADP as agonist,t = 2.391,P<0.05;araehidonic acid as agonist,t =4.057,P<0.01;collagen as agonist t = 2.047, P <0.05).The value of patients taking 100 mg/day aspirin and 75 mg/day clopidgrel at the same time was significantly lower than that of patients taking 100 mg/day aspirin alone(t = 3.646,P <0.01).We found a longer starting aggregation time in patients suspicious to have aspirin resistance than in healthy volunteers in the presence of arachidonic acid.There was good agreement between the results from the two different assays which were used to measured the antiplatelet effect of aspirin(Kappa value = 1)and clopidgrel(Kappa value = O.67).Conclusions It is important that we measure the effect of platelet aggregation inhibitors by the whole blood electrical impedance aggregometry with multi-agonist to evaluate the antiplatelet treatment effect.

[Clopidogrel Resistance of Patients with Coronary Artery Disease and Its Correlation with Platelet Count and Mean Platelet Volume].

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Correlation Between Antiplatelet Resistance and Recurrent Cardiac Ischemic Events of Patients with Acute Myocardial Infarction

Factors associated with clopidogrel resistance and clinical outcomes in ischemic cerebrovascular disease: A retrospective study

Predictive Value of Antiplatelet Resistance on Early Stent Thrombosis in Patients with Acute Coronary Syndrome.

Incidence rates of clopidogrel resistance and influential factors in patients with acute coronary syndrome

Recent Progress in Response Variability of Blood Platelets in Clopidogrel Resistance

Progress of Research on Clopidogrel Resistance in the Patients with Acute Coronary Syndrome

[Risk Factors of Clopidogrel Resistance in the Elderly Patients with Atherosclerotic Cardiovascular Disease].

Quantifying the effect of antiplatelet therapy by whole blood platelet aggregometry

Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume

Monitoring Residual Platelet Activity among Patients with Acute Coronary Syndrome.

Gene Polymorphisms of Insulin Secretion Signaling Pathway Associated with Clopidogrel Resistance in Han Chinese Population.

Effect of CYP2C19 gene Polymorphism on Clopidogrel Resistance After PCI

Study on Genetic Factors of Clopidogrel Resistance

Effect of Clopidogrel on Aspirin Resistance in Acute Coronary Syndrome Patients

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

Whole blood dynamic platelet aggregation counting and 1-year clinical outcomes in patients with coronary heart diseases treated with clopidogrel

Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator

Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome

Clopidogrel-Related High Residual Platelet Reactivity Associated with Estimated Glomerular Filtration Rate in Patients with Acute Ischemic Stroke